Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against…
News
NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay Cancer Relapse
The National Cancer Institute (NCI) has awarded $1.7 million to support the work of a University of Arkansas for Medical…
Stand Up to Cancer Awards $100K for Research About Precursor Multiple Myeloma
Stand Up To Cancer (SU2C) has awarded the 2020 SU2C Sharp Tank Award to Catherine Marinac, PhD, to support her research examining how…
Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
Planned Study Aims for Way to Personalize Multiple Myeloma Treatment
A nonprofit–industry partnership, led by RCSI University of Medicine and Health Sciences of Dublin and SkylineDx, aims to advance genetic testing to better guide doctors…
New HealthTree Feature Promotes Patient-to-Patient Communication
The navigation platform HealthTree has added a feature that enables people with myeloma to communicate with other patients on specific disease topics. Called Myeloma Crowd…
ONCOTracker, Binding Site Team Up to Develop sBCMA Monitoring Test
ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the…
Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show
Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly…
Ide-cel Granted FDA Priority Review for Heavily-treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Bristol Myers Squibb and Bluebird Bio‘s application requesting the approval of…
FDA Grants Fast Track Designation to ‘Off-the-shelf’ CAR T-cell Therapy
The U.S. Food and Drug Administration has granted fast track designation to PBCAR269A, Precision BioSciences‘ donor-derived CAR T-cell therapy for the treatment…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment